Rakibul Islam

Rakibul Islam has a long and varied work experience. Rakibul began their career in 2007 as a Product Executive at Square Pharmaceuticals Ltd., where they explored and launched potential new generic in Bangladesh Pharma Market, and developed marketing strategies for the promotion of the assigned portfolio of generic. In 2009, they were a Research Student at Integrated Regenerative Medicine Center (IGEN), where they tried to see the effects of some proinflammatory cytokines and insulin-like growth factor-I, glucose and serum on insulin receptor and insulin-like growth factor receptor expression. Rakibul then moved on to the University of Oslo in 2012, where they were a Ph.D. Candidate. In 2014, they became a Research Fellow at Harvard Medical School. In 2016, they returned to Oslo University Hospital as a Postdoctoral Researcher. In 2017, they were a Visiting Research Fellow at North Dakota State University. In 2021, they became Head Engineer at Institute for Cancer Genetics and Informatics, Oslo University Hospital, and Chief Scientist and Research and Development Consultant at Rift Labs. Finally, in 2022, they became a Researcher at Oslo University Hospital.

Rakibul Islam has a diverse educational background. Rakibul completed a Bachelor's Degree in Pharmaceutical Sciences from The University of Asia Pacific between 2002 and 2006. Rakibul then went on to earn a Master's Degree in Biomedicine from Linköping University between 2008 and 2010. After that, they obtained a Doctor of Philosophy - PhD in Regenerative Medicine from the University of Oslo (UiO) between 2012 and 2016. In 2014 and 2015, they attended Harvard Medical School and completed the International Research and Training Program in Ophthalmology Research. Additionally, Rakibul Islam has obtained various certifications in AI Product Management Specialization, Human Factors in AI, Agile with Atlassian Jira, Managing Machine Learning Projects, Machine Learning Foundations for Product Managers, and Introduction to Genomic Technologies from Duke University and Coursera between 2021 and 2022.